Introduction
============

Nearly 30 years ago, I proposed that cancer stem cells (CSCs) would be cells blocked at early steps of their genic program, with reiterated expression of embryonic factors responsible for malignant characters and loss of differentiated factors for terminal genomic homeostasis: thus, CSCs would be equivalent to para-embryonic stem cells (p-ESCs) ([@B97]). The main aspects of stem cells (SCs) are self-renewal, pluripotency ([@B90]) and the need for a niche ([@B129]) with proper stereotrophic factors (space, oxygen) and persistent specific signals (ACTIVIN-A, BMP, WNT, LIF, FGF, TGFb) ([@B118]; [@B179]).

*ESCs* arise from the inner cell mass (ICM) of mammalian pre-implantation blastocyst ([@B63]; [@B54]; [Figure 1B](#F1){ref-type="fig"}); they can self-renew symmetrically and indefinitely, maintain the widest pluripotency and generate all cell lineages of the body. This phenomenon requires defined transcription factors (TFs) specifically expressed in SCs, such as OCT4, SOX2, NANOG, STAT3, KLF4, c-MYC et al., that together constitute a pluripotency gene regulatory network (PGRN) ([@B61]; [@B38]; [@B46]). Human ESCs (hESCs) and human embryos express comparable stage-specific embryonic antigens ([@B63]) and can differentiate into the trophectoderm (TE) by BMP4 ([@B180]; [Figure 1B](#F1){ref-type="fig"}). hESCs are epithelial cells ([@B165]), but during *in vitro* differentiation they can acquire a mesenchymal phenotype ([@B42]).

![Human Embryo development. Main phases and structures of the embryogenesis process. **(A)** Zygote to morula transition; **(B)** pre-implantation blastocyst; **(C)** implanted blastocyst; **(D)** early gastrula; **(E)** late gastrula; **(F)** somito-histo-organogenesis; **(G)** fetal growth-differentiation.](fcell-07-00020-g001){#F1}

*MSCs* (mesenchymal stem cells) have a mesenchymal phenotype and markers ([@B165]; [@B42]; [@B160]). MSCs, in Matrigel, grow at the periphery of hESC clusters, have an undifferentiated phenotype and preserve potential expression of pluripotency TFs such as NANOG and OCT4. This indicates that ESCs can undergo epithelial--mesenchymal transition (EMT) without loss of pluripotency, which would be expressed after mesenchymal--epithelial transition (MET) ([@B165]; [@B160]). Cells with mesenchymal features largely lie at the primitive streak (PS) in the embryo and in the tumor stroma ([@B160]; [@B114]; [Figure 1C](#F1){ref-type="fig"}).

*CSCs* are tumor cells that are able to generate all the cell types present in the primary tumor and to form metastases, with identical cell types and hierarchy ([@B99]; [@B19]). CSCs are a small portion of the tumor mass ([@B30]; [@B91]) and are often distinct in tumor-initiating cells (TICs) and tumor migrating cells (TMCs) ([@B64]; [@B13]). TICs have an epithelial phenotype and are able to grow in an anchorage-independent way, to produce spheroids *in vitro* by self-renewal and to initiate tumor development. TMCs have a mesenchymal phenotype, are free, migrating, invasive and generally quiescent, but are able to generate metastases ([@B37]; [@B17]; [@B91]).

Therefore, cells with ESC, MSC, and CSC features are at the basis of both embryo development and cancer process ([Figure 2](#F2){ref-type="fig"}).

![Theoretical similarities between cancer process and ontogenetic development. Correspondence of steps and structures between the cancer process and embryo development.](fcell-07-00020-g002){#F2}

The Tumor Process as Ectopic Rudimentary Ontogenesis
====================================================

Cell of Origin (CSC0): Initial Cancer Stem Cell (i-CSC) as a Reprogrammed Para-ESC
----------------------------------------------------------------------------------

Reprogramming would be the main mechanism for genesis and proliferation of the initial i-CSC (CSC0): it has been shown that somatic cell reprogramming requires a MET at its initiation ([@B86]; [@B142]), with subsequent reversal to a self-renewal and pluripotency state ([@B151]; [@B111]; [@B53]). Thus, I propose that i-CSCs would be equivalent to ESCs, with one important difference: while an ESC has an integral genic program, an i-CSC would have a program impaired in terminal genome homeostasis ([@B77]; [@B151]). In this model, an i-CSC would be a p-ESC ([Figure 3](#F3){ref-type="fig"}). At a molecular level, iCSC genesis would presumably require the following steps in the original cell: (a) De-programming (de-differentiation), by impairment of the systems of genomic homeostasis, carried out by growth modulators (p16, p21, p53, p27, E2A, pRb) ([@B130]; [@B120]; [@B100]; [@B158]) and/or by specific autocrine and paracrine signal pathways (WNT, BMP, LIF, FGF, ERK, TGFb) ([@B143]; [@B77]; [@B144]; [@B26]), with a consequent differentiation loss and reversal to a previous more primitive (mesenchymal/epithelial/undifferentiated) state ([@B151]; [@B145]). (b) Stable PGRN reactivation, by de-regulation of the activity of defined genes (NANOG, OCT4, SOX2, STAT3, ID), with reacquisition of self-renewal and pluripotency ([@B151]; [@B38]; [@B187]). (c) Reprogramming, through ID1 gene expression, that prevents i-CSC/CSC0s (p-ESCs) and their direct progeny from normally differentiating ("blocking event") ([@B188]; [@B175]; [@B107]). ID proteins associate with ubiquitous E proteins, preventing their DNA binding and differentiation activity ([@B139]; [@B173]). ID1 constitutive expression determines neo-angiogenesis, survival, anti-apoptosis and invasion/migration, both in cancer and embryo development.

![Theoretical cancer process. A normal differentiated cell (NDC), in the absence of genomic homeostasis, would be de-programmed and re-programmed to a para-ESC (p-ESC), constituting the initial cancer stem cell (i-CSC or CSC0). **(1)** An i-CSC, by anchorage-independent proliferation, would generate p-ESC progeny, forming an initial tumor *in vivo* (1-red) (or a tumorsphere *in vitro*), corresponding to a pre-implantation blastocyst (TE/ICM). **(2)** The initial tumor would install in a niche with proper factors and develop a primary tumor, mimicking an implanted blastocyst in the endometrium. **(3)** By PGRN activity, primary undifferentiated, pluripotent, slow self-renewing CSCs (CSC1s/TICs) would arise. CSC1s, epigenetically blocked in a ground/primed state, corresponding to the epiblast state, would form a "tumor germinal center," continuously feeding the tumor. **(4)** Through autocrine/paracrine growth, from CSC1s, committed non-self-renewing secondary CSCs (CSC2s) would arise. CSC1s and CSC2s, together, would form a "tumor growth nucleus" corresponding to the epiblast/hypoblast state. **(5)** From CSC1s/CSC2s, tertiary CSCs (CSC3s), with a mesenchymal phenotype (EMT), would be generated. CSC3s would be able to migrate and invade adjoining sites, mimicking delamination of mesodermal precursors at the primitive streak. CSC1s, CSC2s, and CSC3s, together, would form a "tumor expansion module". In the growing primary tumor, favorable conditions (normoxia) would induce CSC3s to proliferate asymmetrically and generate CPCs and, then, CDCs. This would determine a CSC1-CSC2-CSC3-CPC-CDC cell hierarchy and tumor progression, thus mimicking a partial, rudimentary somito-histo-organogenesis process. **(6)** In parallel, unfavorable conditions (hypoxia) would induce CSC3s to migrate as circulating micro-metastases, mimicking the gastrula morphogenetic movements. **(7)** In distant niches with proper EMT signals, CSC3s in the niche would locate as quiescent micro-metastases, mimicking embryonic locations of mesodermal cells at somitogenesis sites. **(8)** Micro-environmental proper MET signals, would induce mesenchymal CSC3 to revert, into epithelial self-renewing CSC1s mimicking gastrular induction (TICs). Self-renewing CSC1s, as TICs, would form a new tumor germinal center and re-initiate the tumor process in metastatic sites, repeating the same steps and reproducing the same cell types and hierarchy of the primary tumor. Tumorsphere figure was adapted from [@B15].](fcell-07-00020-g003){#F3}

Thus, I suggest an iCSC/p-ESC model for the tumor initiation.

Primary Cancer Stem Cells (CSC1s) as Epiblast Cells
---------------------------------------------------

Once generated, i-CSC/CSC0s would survive and symmetrically proliferate early in an anchorage-independent way. Due to its presumed nature as a p-ESC, an i-CSC/CSC0, like an ESC, could generate all cell lineages of the body and, therefore, an initial structure similar to a pre-implantation blastocyst *in vivo* ([Figure 1B](#F1){ref-type="fig"}), or a tumorsphere *in vitro* ([Figure 3](#F3){ref-type="fig"}; [@B75]), that is able to implant in a surrounding microenvironment (niche) ([@B155]), where ID1 proteins would synchronize stemness and anchorage to the niche ([@B113]). Here, the p-ESC direct progeny would proliferate in an anchorage-dependent way, with an autocrine symmetric mechanism, generating primary cancer stem cells (CSC1s), presumably corresponding to epiblast cells ([Figure 1C](#F1){ref-type="fig"}). CSC1s would form a "tumor germinal center" that continuously feeds the neo-forming tumor ([Figure 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). CSC1s would be blocked in a pluripotent undifferentiated/epithelial state (p-ESCs/p-Epi-SCs) ([@B111]; [@B53]), owing to NANOG, OCT4, SOX2, and STAT3 (PGRN) overexpression ([@B176]; [@B103]), or to other genomic conditions inducing ID1 constitutive expression ([@B139]; [@B188]; [@B107]). CSC1s would express self-renewal and pluripotency markers (ALDH1, CD44, CD133) ([@B171]). The number of CSC1s would be low, stable and strictly controlled by the "niche contact", as a limiting factor. ALDH1^+^ CD44^+^ Ki67^+^ CSCs, detected in a central position in mammary tumors, might be hypothetical CSC1s, constituting about 0.084% of the tumor mass ([@B91]). CSC1s would be TICs, like the identified small population of "slow-cycling melanoma cells," essential for continuous tumor growth ([@B136]), or the "long-term renewing" TICs (LT-TICs), that drive tumor feed and metastasis formation in colon cancer ([@B37]).

Thus, I propose that tumor initiation and growth might be continuously sustained by cells (CSC1s) with features (pluripotency and self-renewal) typical of epiblast cells.

Secondary Cancer Stem Cells (CSC2s) as Hypoblast Cells
------------------------------------------------------

When niche contact becomes limiting, only one CSC1 daughter could retain maternal place and phenotype, while the other could acquire a new epithelial phenotype (CSC2) ([@B45]; [@B131]). CSC2s would correspond to hypoblast cells ([Figure 1C](#F1){ref-type="fig"}) and therefore they would not have self-renewal and pluripotency, differently to CSC1s. However, CSC2s might, eventually, revert to CSC1s when a niche contact becomes available ([@B45]; [@B131]). The CSC2 phenotype could occur via the LIF-STAT3-RAS-MAPK-ERK-MYC-ID2 pathway, by NANOG inhibition ([@B82]; [@B181]), ID1/2 switching, loss of stemness/pluripotency ([@B71]; [@B124]) and acquisition of fast paracrine growth ([@B68]). Hypothetical CSC2s might be the CSCs with an ALDH1^+^ CD44^-^ Ki67^+^ profile detected in mammary tumors ([@B91]). The "tumor transient-amplifying cells" (T-TACs) with limited or no self-renewal in human colon cancer, and the "rapidly proliferating main population" surrounding the previously mentioned "slow-cycling melanoma cells" ([@B136]; [@B37]) also could be hypothetical CSC2s. The CSC2 number would be related to the niche volume, nutriments and oxygen quantities ([@B45]; [@B104]; [@B131]): in mammary carcinomas, ALDH1^+^ CD44^-^ Ki67^+^ CSCs (CSC2s) constitute about 5.54% of the tumor mass and lie in a sub-central site, physically distinct from ALDH1^+^ CD44^+^ Ki67^+^ CSCs (CSC1s) ([@B91]). CSC1s and CSC2s, together, would form a presumable "tumor growth nucleus" responsible for tumor expansion ([Figure 3](#F3){ref-type="fig"}).

Thus, I think that tumor growth might result from an autocrine/paracrine signaling-driven proliferation of cells (CSC2s) with features typical of hypoblast cells.

Tertiary Cancer Stem Cells (CSC3s) as Mesoderm Precursor Cells
--------------------------------------------------------------

When the niche microenvironment becomes limiting for growth, certain stereotrophic factors, such as hypoxia, and particular autocrine or paracrine signals (LIF, STAT3, TGFb, WNT, NOTCH) ([@B45]; [@B104]; [@B144]) could induce CSC1s/CSC2s to generate a new phenotype (CSC3), that is able to migrate, invade and search for more favorable survival conditions elsewhere ([@B140]; [@B31]; [@B162]). This phenotype would have mesenchymal features, that would result as a downstream effect of the STAT3-RAS-MAPK-ERK-MYC pathway, regulating ID3/E47 interactions and promoting tumor cell migration and invasion ([@B8]) through expression of mesenchymal genes such as MMPs, SNAIL1, TWIST1, and PRRX1. The CSC3 phenotype would be the result of an EMT that recalls the EMT of mesoderm precursors at the PS ([Figure 1D,E](#F1){ref-type="fig"}). STAT3-SNAIL1 would confer delamination, migration and invasive properties to CSC3s, as TMCs ([@B9]; [@B160]; [@B76]; [@B187]). TWIST1 would increase their invasive properties and, together with PRRX1, would favor installation as micro-metastases in metastatic niches ([@B184]; [@B43]; [@B163]; [@B116]), thus presumably mimicking the onset of somitogenesis at gastrulation sites. ALDH1^-^ CD44^+^ Ki67^-^ CSCs, shown within mammary tumors and located in a peripheral position, at the invasive front, would be presumable CSC3s, constituting about 12.87% of the tumor mass ([@B91]). CSC1s, CSC2s, and CSC3s, together, would form a "tumor progression module" ([Figure 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). I hypothesize that, here, CSC3s with more favorable stereotrophic conditions (normoxia) would become TWIST1^+^ CSC3s, that is able to install and proliferate asymmetrically via ID3/E47, generating more differentiated oligopotent cancer progenitor cells (CPCs). CPCs, in turn, would yield further differentiated cancer cells (CDCs) ([@B45]; [@B20]; [@B104]). The resulting CSC1s/CSC2s/CSC3s/CPCs/CDCs, together, would mimic an ectopic, rudimentary somito-histo-organogenesis process ([Figure 1F](#F1){ref-type="fig"}), and would account for the cell hierarchic heterogeneity in tumor progression ([Figure 2](#F2){ref-type="fig"}), where CSCs would be surrounded and protected by CPCs and CDCs ([@B99]; [@B91]; [@B19]; [Figure 3](#F3){ref-type="fig"}). On the contrary, CSC3s with less favorable stereotrophic conditions (hypoxia) would undergo EMT, becoming SNAIL1^+^ CSC3s, that would be induced to delaminate and migrate as quiescent circulating micro-metastases ([@B45]; [@B140]; [@B104]; [@B31]; [@B162]; [Figure 3](#F3){ref-type="fig"}).

Thus, I propose that tumor progression might occur by appearance of cells (CSC3s) with features of mesoderm precursor cells, that are able to migrate, invade and colonize new sites.

Micro-Metastases and Macro-Metastases as Localization, Induction, and Growth of Gastrula Migrating Cells
--------------------------------------------------------------------------------------------------------

After installation as micro-metastases in defined metastatic sites ([@B6]), by specific niche signals, SNAIL1^+^ CSC3s would undergo MET ([@B22]; [@B17]; [@B116]; [@B159]), reverting to self-renewing CSC1s (TICs), that are able to finally generate macro-metastases ([Figure 2](#F2){ref-type="fig"}, [3](#F3){ref-type="fig"}). Development of macro-metastases would occur via a hypothetical bidirectional genic system TWIST1/ID3/E47/ID1/PRRX1/CD44/PGRN, balanced by TGFb ([@B60]; [@B16]; [@B116]; [@B154]; [@B159]; [@B173]). This system would form a genic switch point in (re)programming: back, for stemness (MET) via PRRX1-CD44-PGRN-ID1 and, forward, for growth-differentiation via ID3-E47-TWIST1 ([@B154]). This would lead, in macro-metastases, simultaneously to self-renewal, angiogenesis and differentiation growth, like in the primary tumor. Presumably, PRRX1 downregulation would suppress the mesenchymal state, restoring the epithelial state (MET) through PGRN reactivation via CD44-ID1. It has been shown that downregulation of PRRX1 expression is necessary for micro-metastases to undergo MET and generate macro-metastases ([@B17]; [@B116]; [@B65]), conferring TIC properties to quiescent CSC3s via an ID3/E47/ID1 switch ([@B115]; [@B65]; [@B173]; [Figure 3](#F3){ref-type="fig"}). ID1 and ID3 are necessary for TIC functions in the genesis of both primary tumors and metastases, sustaining proliferation in early stages via p21 ([@B60]; [@B115]). Moreover, ID1 and ID3 are required for angiogenesis and vascularization of tumor xenografts ([@B95]), necessary for macro-metastasis development. TGFb/ID1 signals promote metastatic colonization via a MET, antagonizing TWIST1 EMT ([@B60]; [@B154]) in normoxic metastatic sites, but not in hypoxic primary tumor sites ([@B104]), where EMT is governed by SNAIL1 ([@B154]). I hypothesize that EMT/MET switching could occur through ID3/E47/ID1 balance ([@B8]; [@B32]; [@B14]; [@B173]) and that it could involve ID3b and ID1b isoforms, generated by alternative splicing of the ID1 and ID3 genes ([@B35]; [@B157]).

Crucial Molecular Factors Common to Embryos and Cancer
======================================================

Pre-implantation Embryos/Initial Tumors (Initiation)
----------------------------------------------------

Pre-implantation embryos lie in unfavorable nutriment and microenvironment conditions. Thus, it is necessary they reach and are installed in a niche that is able to supply proper stereotrophic factors for survival. To this end, molecules such as HSP70, HLA-G, ID, and LIF are crucial both for embryos and cancer.

ID Proteins - ID1, ID2, ID3, and ID4 proteins are highly expressed in normal ontogenetic development, where their function is associated with the primitive proliferative phenotype, and regulate differentiation associating to ubiquitous E proteins ([@B139]; [@B173]). Numerous studies indicate that ID1, ID2, and ID3 have an oncogenic function, whereas ID4 promotes the survival of adult SCs, differentiation and/or differentiation time ([@B126]). ID proteins are key regulators of CSCs and tumor aggressiveness ([@B83]). During distinct stages of breast metastases, ID proteins mediate phenotypic switching of CSCs ([@B154]) and control CSC niches in an autocrine/paracrine way ([@B113]; [@B107]). ID1 has multiple roles in cancer progression, such as implantation in primary and metastatic niches, angiogenesis, CSC survival, chemoresistance, growth, apoptosis inhibition and activation of WNT signaling ([@B89]; [@B113]; [@B107]). In particular, the ID1b isoform has been shown to maintain cell quiescence, confer self-renewal and CSC-like properties, and impair malignancy, inhibiting proliferation and angiogenesis ([@B157]; [@B110]; [@B96]). Thus, ID1b could be related to slow symmetrical self-renewal, niche anchorage and pluripotency maintenance. The ID1a isoform, on the contrary, could be related to fast asymmetrical self-renewal, angiogenesis and evolutionary growth ([@B95]), allowing ID1/ID2 switching, with overcoming of pluripotency and subsequent lineage commitment, like in epi/hypoblast segregation. ID2 enhances cell proliferation by binding pRb, an inhibitor of cell cycle progression, and is directly repressed by p53 ([@B68]; [@B123]). A WNT-bCAT signal increases ID2 expression level and the incidence of CSC-like phenotype, mediating the effects of hypoxia on the breast and colorectal CSC hierarchy ([@B135]; [@B39]). I hypothesize that ID2 would be involved in overcoming stemness/pluripotency, thus leading to cell commitment and fast autocrine/paracrine growth, via LIF-STAT3-RAS-MAPK-ERK-MYC ([@B125]; [@B122]), with ERK blocking NANOG-ID1 ([@B71]; [@B82]; [@B124]). ID1/ID2 switching would occur via ID1-WNT/bCAT-ID2, induced by hypoxia ([@B135]), and might be related to the epi/hypoblast and CSC1/CSC2 transitions. Moreover, ID2 expression might lead, via RAS-MAPK-ERK, to the activation of ID3 genes ([@B8]), with subsequent ID2/ID3 switching and mesenchymal gene expression, namely to EMT. Because the RAS-MAPK-ERK cascade regulates ID3/E2A (E47) interaction ([@B8]), and ID3/E47 balance would determine stem/precursor differentiation ([@B14]), and because ID3 interacts with ID1 ([@B173]), I hypothesize that ID3/E47/ID1 balance would be related to the potential stemness of mesenchymal phenotypes, such as MSCs and CSC3s ([@B115]; [@B32]; [@B159]; [@B14]). In more detail, the ID3a isoform could be related to overcoming of the CSC3 SNAIL1^+^ mesenchymal state and to the stem/progenitor switch via TWIST1 ([@B20]; [@B163]; [@B14]). ID3b isoforms, on the contrary, would be related to the maintenance of the SNAIL1^+^ mesenchymal state of dormant CSC3s and, thus, to a potential EMT/MET switch for reversion to the CSC1 (TIC) phenotype. Indeed, ID3b inhibits vascular formations ([@B35]; [@B49]) and, thus, the possibility of macro-metastasis development, maintaining dormancy. ID4 acts as an ID1/ID2/ID3 inhibitor and promotes E47 binding and transcriptional activity in a differentiation direction ([@B166]; [@B190]; [@B146]). ID4 is a potential tumor suppressor ([@B166]; [@B21]) and suppresses MMP2-mediated invasion of glioblastoma-derived cells by direct inactivation of TWIST1 ([@B132]). I hypothesize that ID4 might be related to terminal differentiation growth, via E47, and to global genomic homeostasis ([@B166]; [@B146]). Thus, ID proteins seem to be crucial factors both in cancer and embryos.

*HSP70* (heat shock protein 70 kDa) molecules are precociously expressed in ontogenesis, from zygotic gene activation, through blastulation, implantation, gastrulation, and organogenesis to fetal maturation ([Figure 1A](#F1){ref-type="fig"}--[G](#F1){ref-type="fig"}) ([@B11]; [@B94]). In early ontogenesis and oncogenesis, HSP70 could be a first system of protection and survival for pre-implantation embryos, as well as for initial tumors. Protective action of HSP70 for pre-implantation embryos might occur at an endocellular level for preventing apoptosis ([@B141]); in effect, HSP70 knockdown renders embryonic cells weaker and apoptotic ([@B109]). A small amount of HSP70.1-3 is necessary for pre-implantation embryogenesis ([@B94]). HSP70 pre-implantation expression includes a constitutive component (HSC70 and HSP70.1-3) from zygote to four-blastomer morula, and a component (HSP70.1-2) inducible by heat and chemical agents in four- to eight-blastomer morula and in blastocyst ([Figure 1A,B](#F1){ref-type="fig"}) ([@B94]). In adult normal tissues, HSP70s are normally absent, except for transient expression in normal mitosis ([@B152]).

HSP70 deregulated overexpression is associated with tumor transformation. In human tumor cells, global profiling of the surface proteome has revealed HSP70.1-2 abundance ([@B152]). HSP70s are highly expressed in various tumor cell types, thus rendered resistant to adverse microenvironments and chemotherapy ([@B149]). In human melanoma cell lines, HSP70.1-2 constitutive expression occurs ([@B40]). During tumor development, HSP70s can be expressed on the cell surface or exported in the circulation ([@B149]). Human tumor cell lines of colon, breast, lungs and melanomas bind anti-HSP70.1 monoclonal antibodies (mAbs) ([@B152]); highly metastatic tumors, but not their primary or poorly malignant counterparts, express membrane HSP70 (mHSP70) ([@B152]). mHSP70^+^ tumors actively release lipidic vesicles (exosomes) with an HSP70^+^ surface ([@B152]). Therefore, I suggest that HSP70s might constitute a first important system of protection and survival in early ontogenesis and oncogenesis.

*HLA-G* (human leukocyte antigen-G) molecules could be a second important system of protection and survival both for initial embryos and cancer. HLA-Gs appear to be evolutionally and genetically linked to HSP70s: heat shock, a major inductor of HSP70.1-2 expression, and arsenite chemical shock also induce HLA-G expression in tumor cell lines ([@B70]; [@B185]). In human pre-implantation embryos, HLA-Gs are expressed as several isoforms, including HLA-G1 and HLA-G5. HLA-G1s are already expressed in two- to eight-blastomer embryos and in all blastocysts as membrane-bound molecules (mHLA-G), whereas, HLA-G5s are expressed only from the blastocyst onwards, as soluble forms (sHLA-G) secreted in biological liquids, or generated by mHLA-G shedding ([@B185]). HLA-Gs circulating in biological fluids might also be associated with extracellular vesicles (EVs) ([@B133]), containing too antigens, ligands, receptors, cytokines, GFs, mRNAs, and miRNAs ([@B34]). Human pre-implantation embryos express and secrete HLA-Gs, the level of which might be predictive of their implantation capacity ([@B185]). HLA-Gs orchestrate the early interaction of human trophoblasts with the maternal niche ([@B57]). HLA-Gs are expressed early in human ICM and ESCs but, later, mainly in invasive TE, and no more in ICM; after implantation, HLA-Gs are expressed in hypoblast, but no longer in epiblast; yolk-sac mesoderm, endothelial cells of developing vessels, mesenchymal cells and progenitor cells express sHLA-Gs ([@B67]; [@B185]; [@B170]) ([Figure 1](#F1){ref-type="fig"}). During pregnancy, sHLA-Gs can be detected in maternal serum. In adult normal tissues, HLA-G constitutive expression is mainly restricted to the fetal extravillous trophoblasts (EVTs), which invade the maternal decidua, rich in NK cells and macrophages ([@B161]).

Tumor and mesenchymal cells also secrete HLA-Gs in EVs ([@B186]; [@B18]). Tumor cells utilize EVs for dictating a defined phenotype to surrounding cells ([@B108]). Recent data show that tumor EVs contain molecules for intercellular communications ([@B34]; [@B133]), that act on and impair the recipient immune cells, favoring immune evasion, initiation, tumor development, angiogenesis, invasion, metastasis, CSC and EMT preservation and chemoresistance ([@B148]; [@B80]). HLA-G expression has been shown in 22/33 primary tumor tissues of human ovarian carcinoma, but not in normal tissue ([@B88]), and in 30% of surgically removed melanoma lesions ([@B182]). In lung cancer, HLA-G1/5 upregulation associates with a high-grade histology, HLA-Ia loss and immunosuppressive IL10 production ([@B168]). Increased HLA-G expression correlates with immune evasion during colorectal cancer progression ([@B51]) and in gastric cancer ([@B41]). These data might, thus, indicate that, in general, in embryos and cancer, HLA-Gs and HSP70s might act not only as protective shields in potentially adverse environments ([@B148]), but also as means for their invasion and colonization ([@B185]). More in detail, it seems that HLA-G1 is preferentially expressed precociously and in more peripheral embryonic structures in an essentially protective scope, whereas HLA-G5 is produced later and in invasive embryonic structures and in tumor metastatic cells, in order to favor protection, invasion, installation and development in the host ([@B138]; [@B148]). HLA-Gs are induced by hypoxia via HIF-1a ([@B134]) and are upregulated by IL10 with autocatalytic feedback ([@B168], [@B169]; [@B154]). HLA-Gs induce IL6 production ([@B169]), and thus activation of the gp130-STAT3 pathway, regulating proliferation, invasion, migration and angiogenesis ([@B76]). In my opinion, all these data suggest that HLA-G molecules could be key inter-players and shared actors in the initiation and maintenance of both embryogenesis and carcinogenesis. Particularly, HLG together to HSP70, would represent an essential system for protection and survival of both embryo and tumor.

Peri-Implantation Embryos/Primary Tumors (Implantation and Growth)
------------------------------------------------------------------

Beyond a certain stage, a blastocyst might develop further only if a supply of nutrients is possible from the outer environment: this would implicate for the embryo the necessity of implantation in the maternal uterus, and for initial tumors in a niche. Blastocyst implantation occurs thanks to the structure and properties of the syncytiotrophoblast ([Figure 1C,D](#F1){ref-type="fig"}; [@B125]) and to a parallel maternal endometrium condition, suited to accepting implantation. The process requires some crucial interacting factors, such as LIF/LIFr, IL6/IL6r, IL10, IL11, GP130, JAK, and STAT3, and correlated signal pathways, leading to the switch from anchorage-independent to anchorage-dependent growth, both in embryos and cancer.

LIF/LIF-r, IL6/IL6-r, gp130-JAK-STAT3 - In peri-implantation, LIF (leukemia inhibitory factor) is crucial: in LIF knockout mice, blastocyst implantation does not occur; in women, LIF strongly increases in the implantation window ([@B147]; [@B1]). Uterine expression of LIF coincides with the onset of blastocyst implantation, and this depends on maternal expression of LIF ([@B12]; [@B29]; [@B147]; [@B189]). LIF is essential for inducing a receptive uterus, but not for embryogenesis ([@B27]). LIF and LIFr expression in the human endometrium suggests a potential autocrine/paracrine function in regulating embryo implantation ([@B33]). In implantation, LIF carries on its biological functions mainly by activation and regulation of the JAK-STAT3, AKT, ERK1-2, and MAPK signal pathways, inducing expression of integrin α5β1, that realizes implantation, endothelial proliferation and endometrial vascularization ([@B29]; [@B147]; [@B125]). LIF-gp130-STAT3 is also linked to HLA-G expression through IL6 and IL10 ([@B167]; [@B189]). In initial embryos, HLA-G expression is a fundamental prerequisite for obtaining pregnancy: indeed, in *in vitro*-fertilized human embryos, only those whose culture surnatant contains sHLA-G are able to perform implantation ([@B52]; [@B2]).

A LIF signal is also expressed at high levels in a wide spectrum of human cancers, including melanomas, skin, kidney, prostate, pancreas and breast cancer, where cell proliferation is stimulated by paracrine and autocrine pathways, as in embryo implantation ([@B33]; [@B78]). The amount of LIF secreted by a tumor seems to regulate cancerogenesis ([@B59]); LIF overexpression in breast cancer patients is significantly associated with an unfavorable rate of survival without relapses ([@B59]). High expression of LIFr identifies very malignant melanocytic lesions at an early stage, and it is a crucial condition for the nevus/implanted melanoma transition ([@B59]). Analysis of 441 melanomas and 90 nevi showed low LIFr expression for all nevus stages, whereas the presence of this receptor starts to increase in dysplastic nevi, with significantly higher expression in primary melanomas (implantation), and even higher in metastatic melanomas ([@B59]), suggesting a striking correlation between LIF/LIFr expression and oncogenesis. LIFr knockdown inhibits melanoma cell migration in wound-healing tests ([@B59]). In general, LIFr activation can promote metastasis and increase the invasion potential of solid tumors ([@B59]). In human colorectal cancer cells and in solid tumors, hypoxia is an important factor inducing LIF mRNA expression, mediated mainly by HIF-2a ([@B189]). TGFb also induces expression of LIF mRNA; LIF induction is important to maintain the self-renewal of glioma-initiating cells and prevent their differentiation ([@B189]). LIF binds to human breast cancer cells and stimulates their proliferation ([@B44]). I hypothesize that in the tumor process, LIF/LIFr might be at the basis of: (a) implantation of the primary tumor (CSC1s) via gp130-JAK-STAT3-ID1, with self-renewal and pluripotency ([@B113]); (b) subsequent paracrine growth (CSC1s/CSC2s) via gp130-JAK-STAT3-RAS-MAPK-ERK-MYC-WNT-ID2 ([@B29]; [@B125]); (c) genesis of cells with a mesenchymal phenotype (CSC3s) via CD44-STAT3-RAS-SNAIL1-MMPs-ID3-TWIST1 ([@B8]; [@B28]; [@B156]; [@B192]; [@B183]). All these data clearly indicate that LIF/LIFr and related signaling pathways are crucial in cancer initiation, implantation, growth and diffusion, in a way that recalls their function in embryo development.

Post-implantation Embryos/Metastatic Tumors (Progression)
---------------------------------------------------------

In the post-implantation embryo, at the PS, cells with a mesenchymal phenotype appear, migrating between epiblast and hypoblast cells ([Figure 1D](#F1){ref-type="fig"}). The mesenchymal phenotype also characterizes metastatic TMCs ([@B140]; [@B160]; [@B116]). The main factors that correlate with the embryonic mesenchymal state, tumor metastases and progression include HLA-G, HSP70, hypoxia, STAT3, CD44, SNAIL1, TWIST1, PRRX1, TGFb, WNT/bCAT, ID, and MMPs. Mesenchymal progenitors derived from hESCs (EMPs) express surface HLA-G1 ([@B186]). Mesenchymal cells and progenitor cells also express HLA-Gs. IL10 selectively induces HLA-G expression in human invasive trophoblasts and monocytes ([@B105]). In mesenchymal CSCs of kidney cancer, HLA-Gs and EVs enhance metastasis and progression ([@B56]). Highly metastatic tumors show the presence of membrane HSP70s ([@B152]). In progression of many cancer types, migration is stimulated by the LIF-STAT3 pathway, constitutively activated, that regulates proliferation, migration, angiogenesis and metastasis ([@B76]; [@B59]). The mesenchymal phenotype is highly characterized by the surface marker CD44.

*CD44* is a cell-surface glycoprotein constituting a signal platform that regulates the expression of genes related to cell-matrix adhesion, migration, proliferation, survival and differentiation in development ([@B117]; [@B177]; [@B183]). The main CD44 receptor is hyaluronic acid (HA), a component of the extracellular matrix (ECM), that envelops tumor cells and bulk, regulating proliferation and motility in cancer progression and metastasis ([@B23]; [@B7]). The CD44-STAT3 complex induces Cyclin D1, MMP9, HIF-a2, c-MYC, TWIST1, cytoskeleton remodeling ([@B156]; [@B183]) and activation of RAS signaling ([@B28]). Expression of CD44s (standard) is ubiquitous, while CD44v (variant) isoforms seem restricted to aggressive tumors ([@B192]). CD44s/CD44v switching is a critical event during EMT ([@B183]).

CD44v (v3, v6, v8) isoforms are CSC markers and have a crucial role in regulation of stemness, self-renewal, tumor initiation, metastasis and chemoresistance ([@B16]; [@B23]; [@B183]; [@B7]). A positive feedback loop couples RAS activation and CD44v isoform expression ([@B28]). CD44/osteopontin (the main component of metastatic niches) interaction activates NANOG-STAT3, OCT4-SOX2-NANOG and c-MYC, namely PGRN, and it is induced by hypoxia via HIF-a1 ([@B81]; [@B128]). CD44 transcription and cell growth are suppressed by p53 ([@B55]). Thus, I hypothesize that CD44v could be a sort of molecular trigger that is able to directly activate PGRN in the initial MET for reprogramming ([@B156]; [@B183]) and, thus, a crucial factor in the generation of signaling for the switch between mesenchymal and epithelial states, usually occurring both in embryos and cancer.

Immunological Aspects Common to Embryos and Cancer: Host Tolerance and Favoring
===============================================================================

HSP70s and HLA-Gs are able to strongly influence many important functions of the immune system. Membrane HSP70s affect NK cell cytotoxicity by acting as recognition/activator ligands ([@B94]; [@B153]), whereas HLA-Gs are able to inhibit practically all immune system components (NK, T, DC, and B cells) ([@B66]; [@B67]; [@B58]; [@B93]; [@B57]; [@B161]; [@B92]). In ESCs and pre-implantation embryos, mHLA-G and sHLA-G block all the uterine immune cells, binding the KIR2DL4 inhibitory receptors on NK cells, and ILT2 (LILRB1) and ILT4 (LILRB2) inhibitor receptors on all the leukocytes and macrophages ([@B66]; [@B85]; [@B170]; [@B161]; [@B133]). Both membrane and soluble HLA-Gs would confer immune-suppressive properties to the cells producing them, in various ways: (a) For HLA-G1, direct interaction with ILT2 and ILT4, determining CD8^+^ T cell apoptosis, NK cell immobilization, and impairment of monocyte/DC differentiation, with a high production of IL4 and IL10 immunosuppressive cytokines ([@B134]; [@B167]; [@B58]; [@B57]; [@B133]). Mesenchymal progenitors derived from hESCs (EMPs) strongly suppress NK and T cells by HLA-G1 ([@B186]). (b) For induction of cascade signaling and biological activity in the host cells, thanks to the factors contained in EVs, internalized by trogocytosis or pinocytosis ([@B138]). CSCs cross-talk with MSCs through EVs containing mRNA and miRNA, identified as the main factors responsible for the phenotypic changes induced in the cells receiving EVs ([@B92]). (c) For amplification of mechanisms and conditions favorable to the cells releasing EVs, with further involvement of other surrounding cells. In human neuroblastomas, tumor cells instruct monocytes to produce and release sHLA-G ([@B137]). HLA-G transfer from antigen-presenting cells (APCs) to activated T cells has been reported in embryos, with reversion of these cells to a regulator phenotype blocking the allo-immune response ([@B133]). A co-culture of activated decidual NK (dNK) cells or peripheral NK (pNK) cells with EVTs results in mHLA-G initial acquisition within 18 h, and complete acquisition in 36 h ([@B161]).

In tumors, HLA-Gs transfer quickly from APCs or cancer cells to T and NK cells, and convert these cells into temporarily suppressor HLA-G^+^ cells ([@B134]). Once acquired by NK cells, HLA-Gs are degraded, and pNK cells revert to their previous cytotoxic phenotype ([@B161]). Both HLA-G5 and HLA-G1 endocytosed by NK cells lead to NFkB pathway activation and, finally, to transcription of immunosuppressor (IL10) and pro-angiogenetic (IL6) factors ([@B133]). It has been shown that pNK cells might acquire via trogocytosis HLA-Gs from a transfected melanoma M8 cell line, and that, after acquisition, NK cells are no longer cytotoxic and are unable to realize immune synapses ([@B84]; [@B161]). In gastric cancer, HLA-G overexpression associates with immune escape and correlates with a local increase of T regulatory cells (TREGs) ([@B41]). NK cytolysis depends on the amount of HLA-G1 expressed, that in malignant tumors can go from 0 to 100%, with complete NK inhibition, reduced local and systemic immunosurveillance and tumor progression ([@B134]; [@B24]). HLA-G1s and HLA-G5s have an additive suppressor effect on NK cytolysis dependent on their level, but HLA-G5 is a more potent inhibitor ([@B193]). Within a population of HLA-G^-^ tumor cells, few HLA-G^+^ cells have significant immune inhibitory effects ([@B84]). HLA-G upregulation also occurs through factors such as cytokines (IL10), stress and chemotherapeutic demethylating agents ([@B137]; [@B182]). IL10 upregulates HLA-G, that induces an immunosuppressive Th2 profile ([@B169]; [@B134]), with further IL10 increase in a vicious circle ([@B105]). Interaction of HLA-G^+^ cells with NK cells also enhances IL6 production, that induces angiogenesis and SC proliferation via gp130-JAK-STAT3-OCT4. The inhibiting effects of HLA-G on NK cells are eliminated by the action of IL15, IL2 and IL12 ([@B161]). CSC immune evasion also occurs through shedding of MIC-A/B, HSP70 and HLA-G1 ([@B4]). It has been shown that highly metastatic tumors, but not their primary or poorly malignant counterparts, are mHSP70^+^, capable of shedding ([@B152]). It is presumable that a high number of molecules such as HSP70, HLA-G, and MIC-A/B released in circulation could lead to ectopic activation and subsequent neutralization of immune cells, without these coming into contact with CSC targets ([@B152]), thus favoring diffusion of metastasis.

Current Anticancer Therapeutic Approaches in Agreement With the I-CSC/P-ESC Model
=================================================================================

Several current partially successful approaches for cancer therapy are in agreement with the i-CSC/p-ESC model, targeting crucial factors common to embryos and tumors, such as HSP70, HLA-G, ID, LIF/LIFr, and CD44. CSCs seem to be preferential targets for NK cells through upregulation of antigens (HSP70, MIC-A/B, FAS, DR5) induced by stress, by which NK cells are capable of targeting (only) quiescent, non-proliferating cells ([@B4]). Thus, in solid tumors, slow-renewing or quiescent CSCs might be more easily killed by NK cells after depletion of proliferating non-CSCs (CPCs) through anti-proliferative therapies ([@B4]).

HLA-Gs are a valid target in cancer therapy ([@B87]; [@B194]); cytotoxicity studies show that HLA-Gs drastically inhibit lysis of human ovarian carcinoma cells, with subsequent immune evasion, and that lysis can be restored by the conformational anti-HLA-G mAb 87G ([@B161]). Interestingly, dNK cells in culture with IL2, IL12, and IL15 lose the acquired surface HLA-Gs by internalization and degradation, reacquiring cytolytic activity ([@B161]). In breast cancer patients treated with NACT (neo-adjuvant chemotherapy), high levels of HLA-Gs/EVs before NACT correlate to tumor progression and the presence of circulating tumor stem-like cells, releasing EVs, while high sHLA-G levels (presumably from tumor lysis) indicate a better clinical outcome ([@B79]). HLA-G expression is induced in the melanoma cell line OCM-1A after treatment with 5-aza-2'-deoxycytidine ([@B182]).

Anticancer therapeutic approaches based on endocellular and exocellular HSP70s have been carried out ([@B36]; [@B149]; [@B73]). It has been reported that mHSP70^+^ tumors actively release lipid vesicles (exosomes) with an HSP70^+^ surface, and that they can attract already activated NK cells (but not resting NK cells) ([@B152]), causing their ectopic degranulation and neutralization. The TKD peptide (14 amino acids common to all HSP70s), combined with IL2 low doses, has been found to stimulate NK cell migratory and cytolytic activity against HSP70^+^ tumor cells ([@B152]). A murine antibody anti-TKD (cmHsp70.1 mAb) binds all human vital tumor cell lines of colon, breast, lungs and melanomas; thus, HSP70s could be an immune-therapeutic target in a wide spectrum of tumor types ([@B149]; [@B152]). In fact, cmHsp70.1 mAb injected into mice with CT26 colon tumors can significantly reduce the bulk of mHSP70^+^ tumors and increase survival via ADCC induction, that can be further enhanced by NK cells pre-activated with TKD/IL2 ([@B152]).

ID genes and proteins are a promising target in cancer therapy for inhibiting tumor cells and their supply in the blood ([@B10]; [@B47]; [@B69]). ID protein inhibition by a peptide aptamer induces cell cycle arrest and apoptosis in ovarian cancer cells ([@B101]). Suppression of invasion and metastasis in aggressive salivary and breast cancer cells is targeted through inhibition of ID1 expression ([@B48]; [@B106]). Inactivation of ID1 genes induces sensitivity of prostate cancer cells to chemotherapeutic drugs ([@B178]). Co-suppression of ID1 and ID3 results in a significant reduction in the proliferation rate, invasiveness and anchorage-independent growth, reduced angiogenesis and increased apoptosis in small-cell lung cancer ([@B25]), and significantly reduces the ability of gastric cancer cells to form peritoneal metastases ([@B164]). Moreover, ID1 and ID3 knockdown inhibits the metastatic potential of pancreatic cancer, both for proliferation and migration ([@B150]). Targeting ID1 and ID3 by a specific peptide aptamer induces E-box promoter activity, cell cycle arrest and apoptosis in breast cancer cells ([@B102]). TGFb receptor inhibitors target the CD44^high^/Id1^high^ glioma-initiating cells in human glioblastoma ([@B5]). It has been shown that ID2 knockdown by an inhibitor of WNT-bCAT signaling markedly suppresses the formation of CSC spheres *in vitro*, and metastases *in vivo* ([@B135]), by inhibition of CSC-like phenotypes ([@B72]).

LIFr expression is a crucial condition for nevus/implanted melanoma transition; LIFr knockdown inhibits migration of melanoma cells in wound-healing tests; thus, LIFr could be a potential target for developing therapies in initial tumor interventions ([@B59]). Neutralizing antibodies knock down activity or expression of LIF and reduce *in vitro* the stem cell-like properties of murine slow-growing CSCs ([@B3]).

CD44 is a biomarker and therapeutic target in CSCs ([@B156]; [@B183]), and CD44v is a promising approach for elimination of CSCs ([@B74]; [@B119]; [@B183]). In breast cancer, cells with an EMT phenotype can be inhibited by Abs specific for CD44 ([@B183]); knockdown of CD44 induces differentiation of breast CSCs and is a promising differentiation therapy ([@B127]). CD44 targeting reduces tumor growth and prevents post-chemotherapy relapse of human breast cancer xenografts ([@B98]). Inhibition of CD44v3 and v6 by A5G27 peptide copolymer blocks tumor invasion and metastatic colonization ([@B191]). DNA vaccination with CD44v isoforms reduces mammary tumor local growth and lung metastases ([@B172]).

Immunological approaches to target CSCs have been carried out, and through CSC vaccination, significant antitumor immunity can be conferred ([@B112]; [@B121]). For improving the efficacy of breast cancer treatment, a combination therapy has been used, that permits targeting of both CSC-like and bulk tumor cells ([@B174]). Thus, it is evident that many current therapeutic strategies are addressed to target crucial factors, common to embryos and cancer, at the basis of this i-CSC/p-ESC model.

Discussion and Conclusion: Proposals for Innovative Cancer Therapy and Prophylaxis Strategies
=============================================================================================

Considerations for a Proper Antitumor Therapeutic Strategy
----------------------------------------------------------

From the numerous experimental data reported above, it is evident that embryo and tumor development occurs in very similar physio-pathological conditions of immune tolerance by the host, which accepts and even favors them. Anticancer therapies carried out so far, targeting separately the factors HLA-G, ID, LIF, HSP70, and CD44, have got important positive, but only partial and non-resolutive, results. This limit might be due to several factors: (a) a particular hierarchic tumor structure, immunologically protective for CSCs, surrounded by CPCs and CDCs ([@B114]; [@B99]; [@B91]; [@B4]; [@B19]); (b) interconversion among CSCs (CSC1/CSC2/CSC3/CSC1) via ID1, ID2 and ID3 proteins ([@B64]; [@B13]; [@B37]; [@B17]; [@B131]; [@B38]; [@B19]); (c) the presence of HLA-G and HSP70 on the surface of CSCs and CPCs, with impairment of various immune surveillance mechanisms, NK activity in particular ([@B141]; [@B138]; [@B148]; [@B152]); (d) anti-proliferative chemotherapies, that only eliminate actively proliferating CCs (CSC2s and CPCs), but spare slow-renewing CSCs (CSC1s) in niches, or quiescent circulating CSCs (CSC3s), and non-proliferating CDCs ([@B4]; [@B174]); (e) release into the circulation of a high quantity of HSP70 by shedding, exosomes or chemotherapeutic necrosis ([@B149]; [@B152]), attracting ectopically activated NK cells and neutralizing them at a distance from CSC targets ([@B152]); (f) release into the circulation, by shedding, EVs or chemotherapeutic necrosis, of high amounts of HLA-G, that is able to block any immune mechanism, or even instruct normal cells to favor the tumor ([@B66]; [@B85]; [@B138]; [@B58]; [@B93]; [@B92]); (g) negative collateral effects of anti-angiogenetic therapies that, by blocking tumor vascularization, might induce hypoxia and a subsequent increase of metastatic CSCs (CSC3s) ([@B31]).

General Suggestions for a Potential Multi-Target Multistep Cancer Therapy
-------------------------------------------------------------------------

On the basis of the previous considerations, I suggest some general indications for a multistep multi-target therapeutic strategy. To this end, I think that it would be necessary to make use of "micro-antibodies" (mi-Abs), which are artificial, chemically synthetized short chains of amino acids, copied from fully functional natural antibodies ([@B62]). Their small size allows them to leave the circulation quickly and reach specific target sites in the tissues, normally unapproachable for mAbs. mi-Abs are poorly immunogenic and do not stimulate an immune response versus the host. mi-Abs show neutralizing properties versus viruses, such as HIV, infecting cells *in vitro* ([@B50]). All these mi-Ab properties might consent the following antitumor therapeutic strategy, leading to progressive back-dismantling of the tumor hierarchic organization, selectively targeting the diverse tumor cell populations in a defined multistep sequence: (a) co-culture of autologous peripheral blood mononuclear cells (PBMCs) with IL15, IL12 and IL2, to restore them from the effects of HLA-G ([@B161]) and dispose of HLA-G-free PBMCs, to be used in next steps; (b) tumor biopsy for the selection of the various populations: differentiated non-proliferating cells (CDCs), non- or slow-proliferating SCs (CSC1s and CSC3s), actively proliferating cells (CSC2s and CPCs); (c) co-culture of HLA-G-free PBMCs with each selected tumor population, and "in toto" tumor populations, previously treated with anti-HLA-G and anti-HSP70 mi-Abs, allowing *in vitro* PBMC sensitization without conditioning; (d) anti-HLA-G and anti-HSP70 prophylaxis of the subject by specific mi-Abs; (e) reinfusion of anti-CDC-sensitized PBMCs and/or chemotherapeutic treatment, to reduce the tumor bulk and expose the internal cell populations ([@B4]; [@B174]), thus making them more approachable in the next steps; (f) chemotherapeutic anti-proliferative treatment of the subject to eliminate fast-proliferating CSC2s and CPCs, upon protection with anti-HLA-G and anti-HSP70 neutralizing mi-Abs; (g) treatment of the subject with anti-CD44v and anti-ID1/ID3 mi-Abs to neutralize circulating CSC3s from an eventual CSC3/CSC1 transition (MET), and CSC1s in niches from anchorage and self-renewal ([@B98]; [@B25]; [@B191]); (h) treatment of the subject with anti-LIF/LIFr and anti-ID1/2 mi-Abs to prevent or block CSC1 implantation in niches and angiogenesis, CSC migration by activation of the LIF-STAT3 pathway, and a possible CSC1/CSC2/CSC3 transition (EMT) ([@B135]; [@B3]; [@B59]; [@B72]); (i) treatment of the subject with anti-HLA-G, anti-HSP70, anti-CD44, anti-ID1/ID2/ID3 and anti-LIF/LIFr mi-Abs for general prophylaxis; (ii) final treatment with "in toto" sensitized HLA-G-free PBMCs to restore natural immunological and physiological conditions in the host.

Considerations and Suggestions for Potential Cancer Prophylaxis
---------------------------------------------------------------

On the basis of the i-CSC/p-ESC model, it might be logically and biologically possible to use anti-HSP70/HLA-G (Qa-2 in mouse)/ID/LIF-LIFr/CD44 mi-Abs for antitumor prophylaxis. Periodical treatments with mi-Abs at defined times and in defined ways could protect healthy subjects from arising tumors (i-CSC/CSC0s) or implanting initial tumors (CSC1s). The validity of this hypothesis might be tested in appropriate animal models, inoculating before, together and after mi-Ab treatments: (a) CSCs of various human tumor types, in nude mice; (b) CSCs of various mouse tumor types in normal autologous mice. Verifying tumor development, an eventual absence of tumors with the treatment before or together with CSC inoculation would indicate a preventive effect of the mi-Abs while, with the subsequent treatment, it could also indicate a drainage effect of the mi-Abs versus initial tumors. The use of mi-Abs for periodical prophylaxis could be evaluated in relation to the subject age, in general. In particular, in women, it could be considered in relation to an eventual pregnancy, because all the mi-Ab tumor targets are crucial embryonic factors.

In conclusion, I hope that this work might make a valid contribution for a better vision of the cancer, and that it might stimulate the interest of others to debate and verify some validity of the ideas expressed, as well as to test the therapeutic potential of the suggested proposals.
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